Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oncology
Studies add new findings to oncology body of knowledge
May 5th, 2005
New findings from the United States and France describe advances in oncology. Study 1: Immunocompetent breast cancer models test Eph receptor-targeted therapy. According to published research from the United States, "EphA2, a receptor tyrosine kinase, is elevated in many invasive human breast cancers, and the majority of EphA2 remains unphosphorylated. The successful attachment of ligand ephrin-A1 present on the surface of adjacent cells to EphA2 initiates EphA2 phosphorylation leading to its turnover. In vivo efficacy of various approaches targeting EphA2 for breast cancer therapy is usually evaluated in nude mice bearing human breast cancer...
Source: Women's Health Weekly (2005-05-05)
|
